EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hybrid Population Pharmacokinetic–Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn’s Disease

Kei Irie iD, Phillip Minar, Jack Reifenberg, Brendan M Boyle, Joshua D Noe, Jeffrey S Hyams, Tomoyuki Mizuno

Clinical Pharmacokinetics · 2025-11 · 64 (11) · 1669-1679

DOI: 10.1007/s40262-025-01564-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 30.08.2025. Verfasst von Kei Irie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Machine Learning, Models, Biological. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Population pharmacokinetic (PK) model-based Bayesian estimation is widely used for dose individualization, particularly when sample availability is limited. However, its predictive accuracy can be compromised by factors such as misspecified prior information, intra-patient variability, and uncertainties in PK variations. In this study, we developed a hybrid approach that combines machine learning (ML) with population PK-based Bayesian methods to improve the prediction of infliximab concentrations in children with Crohn's disease. METHODS: We calculated prediction errors between Bayesian-estimated and observed infliximab concentrations from 292 measurements across 93 patients. Incorporating clinical patient features, we explored various ML algorithms, including linear regression, random forest, support vector regression, neural networks, and XGBoost to correct the Bayesian-based prediction errors. The predictive performance of these ML models was assessed using root mean square error (RMSE) and mean prediction error (MPE) with 5-fold cross-validation. RESULTS: For Bayesian estimation alone, the RMSE and MPE were 4.8 µg/mL and - 0.67 µg/mL, respectively. Among the ML algorithms, the XGBoost model demonstrated the best performance, achieving an RMSE of 3.78 ± 0.85 µg/mL and an MPE of - 0.03 ± 0.69 µg/mL in 5-fold cross-validation. The ML-corrected Bayesian estimation significantly reduced the absolute prediction error compared with Bayesian estimation alone. CONCLUSION: This hybrid population PK-ML approach provides a promising framework for improving the predictive performance of Bayesian estimation, with the potential for continuous learning from new clinical data to enhance dose individualization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabMachine LearningModels, BiologicalGastrointestinal AgentsHumansChildBayes TheoremAdolescentMaleFemaleYoung AdultAlgorithmsAdult

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • University of Cincinnati School of Medicine, Cincinnati, OH, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, WI, USA.

ORCID-Profile: Kei Irie

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Irie, K., Minar, P., Reifenberg, J., Boyle, B. M., Noe, J. D., Hyams, J. S., & Mizuno, T. (2025). Hybrid Population Pharmacokinetic–Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn’s Disease. Clinical Pharmacokinetics, 64(11), 1669-1679. https://doi.org/10.1007/s40262-025-01564-7

Vancouver

Irie K, Minar P, Reifenberg J, Boyle BM, Noe JD, Hyams JS, et al. Hybrid Population Pharmacokinetic–Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn’s Disease. Clinical Pharmacokinetics. 2025;64(11):1669-1679. doi:10.1007/s40262-025-01564-7

BibTeX
@article{Irie2025,
  author = {Irie, Kei and Minar, Phillip and Reifenberg, Jack and Boyle, Brendan M and Noe, Joshua D and Hyams, Jeffrey S and Mizuno, Tomoyuki},
  title = {Hybrid Population Pharmacokinetic–Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn’s Disease},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  volume = {64},
  number = {11},
  pages = {1669--1679},
  doi = {10.1007/s40262-025-01564-7}
}
Kostenlos starten →